The ultrasonically treated nanoliposomes containing PCV2 DNA vaccine expressing gC1qR binding site mutant Cap is efficient in mice.
The ultrasonically treated nanoliposomes containing PCV2 DNA vaccine expressing gC1qR binding site mutant Cap is efficient in mice.
复制标题
经过超声处理的纳米脂质体含有表达 gC1qR 结合位点突变体 Cap 的 PCV2 DNA 疫苗，对小鼠有效
DOI：
10.3389/fmicb.2022.1077026
复制
发表时间：
2022
影响因子：
5.2
通讯作者：
Huang, Yong
中科院分区：
文献类型：
--
作者：
Du, Qian;Shi, Tengfei;Wang, Huaxin;Zhu, Changlei;Yang, Nan;Tong, Dewen;Huang, Yong
关键词：
如今，疫苗被广泛用于预防猪圆环病毒2型(PCV2)感染导致的支出，但该病毒仍在猪之间传播。目前的PCV2疫苗都依赖于Cap的免疫原性，但我们以前的研究发现，Cap也是通过与宿主gC1qR相互作用而介导PCV2感染诱导的免疫抑制的主要成分。因此，新的疫苗仍然是预防和控制PCV2的必要疫苗。在本研究中，我们构建了一种表达gC1qR结合位点突变体Cap的新型PCV2 DNA疫苗。我们将内含子A和WPRE元件引入到载体中，以提高Cap的表达水平，并将IL-2分泌信号肽融合到Cap的N端，以介导Cap的分泌。我们还筛选和选择了趋化因子CXCL12、CCL22和CCL25来迁移树突状细胞。此外，我们还将载体与聚乙二醇胺包埋，然后将其超声细化到纳米尺寸，以增强载体的入射性。动物实验表明，表达gC1qR结合位点突变体的新型PCV2 DNA疫苗在小鼠体内诱导的体液免疫和细胞免疫应答均强于表达野生型和非超声处理的PCV2 DNA疫苗，并能保护小鼠免受PCV2感染和肺部病变的影响。结果表明，表达gC1qR结合位点突变体Cap的新型PCV2 DNA疫苗具有一定的开发价值，为新型PCV2疫苗的开发提供了新的思路。
Nowadays, vaccines are broadly used to prevent porcine circovirus type 2 (PCV2) infection-induced expenditures, but the virus is still spreading among pigs. The current PCV2 vaccines all rely on the immunogenicity of Cap, yet our previous studies found that Cap is also the major component mediating the PCV2 infection-induced immune suppression through its interaction with host gC1qR. Thereby, new vaccines are still necessary for PCV2 prevention and control. In this study, we constructed a new PCV2 DNA vaccine expressing the gC1qR binding site mutant Cap. We introduced the Intron A and WPRE elements into the vector to improve the Cap expression level, and fused the IL-2 secretory signal peptides to the N-terminal of Cap to mediate the secretion of Cap. We also screened and selected chemokines CXCL12, CCL22, and CCL25 to migrate dendritic cells. In addition, we contained the vectors with PEI and then ultrasonic them into nano size to enhance the entrance of the vectors. Finally, the animal experiments showed that the new PCV2 DNA vaccine expressing the gC1qR binding site mutant Cap could induce stronger humoral and cellular immune responses than the PCV2 DNA vaccine expressing the wild-type Cap and the non-ultrasonic treated PCV2 DNA vaccine in mice, and protect the mice from PCV2 infection and lung lesions. The results indicate the new PCV2 DNA vaccine expressing the gC1qR binding site mutant Cap has a certain development value, and provide new insight into the development of novel PCV2 vaccines.
登录
查看更多内容
猪体内表达 PCV2 衣壳蛋白的腺病毒疫苗的免疫原性
影响因子：
5.5
作者：
Li, Delong;Du, Qian;Tong, Dewen
通讯作者：
Tong, Dewen
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
5.5
作者：
通讯作者：
--
影响因子：
3.7
作者：
Finsterbusch, Tim;Steinfeldt, Tobias;Mankertz, Annette
通讯作者：
Mankertz, Annette
影响因子：
3.8
作者：
Sahoo, Monalisa;Pathak, Mamta;Sahoo, Nihar Ranjan
通讯作者：
Sahoo, Nihar Ranjan